Cargando…
Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?
Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect wa...
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690547/ https://www.ncbi.nlm.nih.gov/pubmed/26719846 http://dx.doi.org/10.1093/ofid/ofv175 |
| _version_ | 1782407028282490880 |
|---|---|
| author | Grard, Soazic Catho, Gaud Valour, Florent Bouaziz, Anissa Perpoint, Thomas Braun, Evelyne Biron, François Miailhes, Patrick Ferry, Tristan Chidiac, Christian Souquet, Pierre-Jean Couraud, Sébastien Lina, Gérard Goutelle, Sylvain Veziris, Nicolas Dumitrescu, Oana Ader, Florence |
| author_facet | Grard, Soazic Catho, Gaud Valour, Florent Bouaziz, Anissa Perpoint, Thomas Braun, Evelyne Biron, François Miailhes, Patrick Ferry, Tristan Chidiac, Christian Souquet, Pierre-Jean Couraud, Sébastien Lina, Gérard Goutelle, Sylvain Veziris, Nicolas Dumitrescu, Oana Ader, Florence |
| author_sort | Grard, Soazic |
| collection | PubMed |
| description | Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect was neuropathy. We propose that LNZ should be reclassified among bactericidal second-line drugs. |
| format | Online Article Text |
| id | pubmed-4690547 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46905472015-12-30 Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four? Grard, Soazic Catho, Gaud Valour, Florent Bouaziz, Anissa Perpoint, Thomas Braun, Evelyne Biron, François Miailhes, Patrick Ferry, Tristan Chidiac, Christian Souquet, Pierre-Jean Couraud, Sébastien Lina, Gérard Goutelle, Sylvain Veziris, Nicolas Dumitrescu, Oana Ader, Florence Open Forum Infect Dis Brief Reports Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect was neuropathy. We propose that LNZ should be reclassified among bactericidal second-line drugs. Oxford University Press 2015-12-22 /pmc/articles/PMC4690547/ /pubmed/26719846 http://dx.doi.org/10.1093/ofid/ofv175 Text en © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com. |
| spellingShingle | Brief Reports Grard, Soazic Catho, Gaud Valour, Florent Bouaziz, Anissa Perpoint, Thomas Braun, Evelyne Biron, François Miailhes, Patrick Ferry, Tristan Chidiac, Christian Souquet, Pierre-Jean Couraud, Sébastien Lina, Gérard Goutelle, Sylvain Veziris, Nicolas Dumitrescu, Oana Ader, Florence Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four? |
| title | Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four? |
| title_full | Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four? |
| title_fullStr | Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four? |
| title_full_unstemmed | Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four? |
| title_short | Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four? |
| title_sort | linezolid in the starter combination for multidrug-resistant tuberculosis: time to move on to group four? |
| topic | Brief Reports |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690547/ https://www.ncbi.nlm.nih.gov/pubmed/26719846 http://dx.doi.org/10.1093/ofid/ofv175 |
| work_keys_str_mv | AT grardsoazic linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT cathogaud linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT valourflorent linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT bouazizanissa linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT perpointthomas linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT braunevelyne linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT bironfrancois linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT miailhespatrick linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT ferrytristan linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT chidiacchristian linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT souquetpierrejean linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT couraudsebastien linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT linagerard linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT goutellesylvain linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT vezirisnicolas linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT dumitrescuoana linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour AT aderflorence linezolidinthestartercombinationformultidrugresistanttuberculosistimetomoveontogroupfour |